Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity
- PMID: 38558891
- PMCID: PMC10979369
- DOI: 10.5114/reum/185429
Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity
Abstract
Axial spondyloarthritis (axSpA) is an inflammatory joint disease, in which the dominant symptom is inflammatory back pain. It affects approximately 1% of the population, with a higher incidence in males. Spinal pain associated with spondyloarthritis is referred to as inflammatory back pain. In clinical practice, it is extremely important to be able to assess the activity of inflammatory back diseases and to select appropriate treatment and monitor the therapy. Currently, two main tools are used for assessment of the activity of axial spondyloarthritis: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS (Ankylosing Spondylitis Disease Activity Score). The BASDAI is a tool used for years for assessment of disease activity, determining eligibility for treatment, and making decisions about continuation of therapy. Since BASDAI depends entirely on patient self-assessment, it is considered less objective than the ASDAS index. In turn, the latter includes not only answers to questions provided by the patient but also a parameter of inflammation such as erythrocyte sedimentation rate or C-reactive protein (CRP). Additionally, increasing numbers of studies report advantages of the ASDAS index over BASDAI. Moreover, as indicated by ASAS/EULAR (Assessment in Spondyloarthritis International Society/European Alliance of Associations for Rheumatology) 2022, ASDAS, especially ASDAS-CRP is the preferred tool for assessment of the activity of axSpA, whereas BASDAI is used only when the evaluation of the ASDAS is not possible. This paper presents the definition and symptoms of axSpA and reviews the latest research on ASDAS and BASDAI, with emphasis on the objectivity of the ASDAS assessment also presenting the doubts and limitations concerning this tool.
Keywords: ASDAS; BASDAI; ankylosing spondylitis; disease activity index; spondyloarthritis.
Copyright: © 2024 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.Int J Rheum Dis. 2019 Dec;22(12):2206-2212. doi: 10.1111/1756-185X.13735. Epub 2019 Nov 13. Int J Rheum Dis. 2019. PMID: 31721427
-
The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.J Clin Rheumatol. 2017 Aug;23(5):267-272. doi: 10.1097/RHU.0000000000000522. J Clin Rheumatol. 2017. PMID: 28661926
-
Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.Rheumatol Int. 2015 Jun;35(6):981-9. doi: 10.1007/s00296-014-3168-y. Epub 2014 Nov 4. Rheumatol Int. 2015. PMID: 25366469
-
How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice.Curr Rheumatol Rep. 2024 May;26(5):170-177. doi: 10.1007/s11926-024-01141-0. Epub 2024 Feb 19. Curr Rheumatol Rep. 2024. PMID: 38372873 Review.
-
Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety.Clin Rheumatol. 2024 Aug;43(8):2391-2402. doi: 10.1007/s10067-024-07027-x. Epub 2024 Jun 14. Clin Rheumatol. 2024. PMID: 38874670
Cited by
-
A full-spectrum Boswellia serrata extract with enhanced bioavailability, and its co-delivered system with curcumin alleviate pain and stiffness associated with moderate spondylitis: a randomized double-blind, placebo-controlled, 3-arm study.Front Pharmacol. 2025 Jul 1;16:1577429. doi: 10.3389/fphar.2025.1577429. eCollection 2025. Front Pharmacol. 2025. PMID: 40667507 Free PMC article.
-
The role of magnetic resonance imaging in monitoring patients with axial spondyloarthritis.Reumatologia. 2025 May 30;63(3):152-158. doi: 10.5114/reum/200528. eCollection 2025. Reumatologia. 2025. PMID: 40678031 Free PMC article.
-
Central Sensitization and Its Role in Persistent Pain Among Spondyloarthritis Patients on Biological Treatments.Medicina (Kaunas). 2025 Feb 12;61(2):319. doi: 10.3390/medicina61020319. Medicina (Kaunas). 2025. PMID: 40005436 Free PMC article.
-
Adherence, Fears, and Beliefs about Biologic Drugs in Rheumatoid Arthritis Patients: A North African Pilot Study.Mediterr J Rheumatol. 2024 Dec 31;35(4):623-633. doi: 10.31138/mjr.200823.afa. eCollection 2024 Dec. Mediterr J Rheumatol. 2024. PMID: 39886288 Free PMC article.
-
Difficult-to-Manage Axial Spondyloarthritis.Mediterr J Rheumatol. 2024 Dec 31;35(Suppl 3):542-548. doi: 10.31138/mjr.131124.dma. eCollection 2024 Dec. Mediterr J Rheumatol. 2024. PMID: 39974587 Free PMC article. Review.
References
-
- Erol K, Gok K, Cengiz G, et al. . Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis. Acta Reumatol Port 2018; 43: 32–39. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous